James McCloskey, MD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP give a brief synopsis of AML, including its definition, the different types of the condition, and a typical patient’s journey.

Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.

Cole McCoy, PharmD, shares recent changes in the AML treatment landscape, including updates to the NCCN guidelines.

Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.

Cole McCoy, PharmD, and Dr James McCloskey explain first-line treatment options for different types of AML, how genetic mutation affect treatment decisions, and the treatment option for patients with AML that are unfit for intensive chemotherapy.

Medical experts elaborate on the AG221-AML-005 and AGILE studies and their results, as well as how we assess first-line treatment response.

The panel describes the various roles and responsibilities for each member of an AML management care team.

Dr James McCloskey discusses patient selection for AML maintenance therapy, as well as novel agents that are being evaluated in this setting.

Cole McCoy, PharmD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP explain the additional agents being studied as maintenance therapy options.

James McCloskey, MD, analyzes result data from the QUAZAR AML-001 trial that focused on oral azacitidine.

Cole McCoy, PharmD, details his experiences with oral maintenance therapies, specifically oral azacitidine.

Cole McCoy, PharmD, considers if maintenance therapy is standard of care and what is involved with appropriate transitions upon discharge.

Drs McCoy and McCloskey discuss relapsed/refractory AML, including treatment goals and options.

The panel concludes with their thoughts on the future of the AML treatment landscape.